Kornimate/medical-research-clean huggingface dataset:
extended follow-up of women who received one, two, and three doses of the hpv vaccine in the costa rica vaccine trial (cvt), escuddo-cvt study

Conditions: Human Papillomavirus Infection; Human Papillomavirus-Related Malignant Neoplasm

Summary: this study is extending follow up of women who participated in the costa rica vaccine trial (cvt) and received one dose or two doses of the human papillomavirus (hpv) vaccine, along with a group of women who received three doses. it also studies the stability of hpv defenses in these groups of women for up to 20 years after initial vaccination. studying samples of blood in the laboratory may provide information on how long one, two, and three doses of the vaccine provide protection against hpv. the results of this study may also help researchers learn whether one dose of hpv vaccine is enough to protect against hpv.

primary objectives: i. estimate the change in antibody levels between years 11 and 20. ii. estimate the proportion of individuals who become seronegative (i.e.: serorevert) between years 11 and 20. secondary objectives: i. assess the prevalence and distribution of type-specific hpv infections at least 18 years after hpv vaccination. ii. assess the number and type of premalignant lesions present at least 18 years after vaccination. iii. for each dose regimen, characterize hpv-specific memory b cells and long-lived plasma cells present at least 18 years after hpv vaccination, and compare these characteristics with results from earlier time points. outline: this is an observational study. patients complete a short questionnaire regarding risk factors for hpv infection and undergo collection of blood samples for testing hpv16 and hpv18 levels on study.

Eligibility criteria:
inclusion criteria: * participation in the cvt long term follow-up (ltfu) study exclusion criteria: * a random subset of the three-dose women
comparison of antibody levels in children and adolescents after initiation of insulin therapy by either insulin aspart or soluble human insulin

Conditions: Diabetes; Diabetes Mellitus, Type 1

Summary: this trial is conducted in europe. this is a single-centre, retrospective trial aiming at comparing the antibody levels in children and adolescents.


Eligibility criteria:
inclusion criteria: * informed consent obtained before any trial-related activities * any subjects at onset of type 1 diabetes * treatment with either insulin aspart and soluble human insulin or soluble human insulin and isophane human insulin / mixtard® for at least 9 months from the time of diagnosis of diabetes exclusion criteria: * treatment with immunosuppressive agents * for the insulin aspart + isophane human insulin: treatment with insulin analogues other than insulin aspart or treatment with fast acting human insulin for a period of 7 days or more during the treatment period * for the soluble human insulin and isophane human insulin group: treatment with insulin analogues * other diseases influencing immune response * unable or unwilling to provide consent
botulinum toxin for carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: to compare local steroid injections to local botulinum toxin a injection in a double-blinded study.

to compare local steroid injections to local botulinum toxin a injection in a double-blinded study. the goal is to investigate if botulinum toxin a injections are effective for carpal tunnel syndrome compared to steroid injections in terms of pain relief and length of symptom alleviation.

Eligibility criteria:
inclusion criteria: * any individual with symptoms of carpal tunnel syndrome and a diagnosis of cts either clinically or via emg will be included into this study. there will be a total of 20 subjects displaying symptoms of cts. the gender of the subjects will not determine enrollment. there is no requirement of male to female ratio for this study. there is no age cut-off or minimal age requirement to enroll in the study. no specific racial or ethnic restrictions will be present for this study. female subjects of childbearing potential (not surgically sterile or postmenopausal for at least 2 years) must have a negative pregnancy test at screening. exclusion criteria: 1. any individual who has a diagnosis of cts (by emg or other means) but no symptoms of cts will be excluded from this study. 2. vulnerable subjects as defined as children, pregnant women, those with limited autonomy, decisional incapacity and prisoners will not be enrolled in this study. 3. individuals with any history of carpal tunnel release surgery and recurrent or persistent symptoms will be excluded form this study. 4. subject is pregnant or lactating.
changes in abdominal tissues induced by magnetic device - mri evaluation

Conditions: Fat Burn

Summary: the study is a prospective multi-center open-label single-arm study. the subjects will be enrolled and assigned into a single study group. subjects will be required to complete four (4) treatment visits and three follow-up visits, 2 months, 6 and 12 months after the final treatment. at the baseline visit photographs of the abdomen will be taken. in addition, adipose/muscle layer thickness will be measured with the magnetic resonance imaging and the subject's weight will be recorded. safety measures will include documentation of adverse events (ae) including subject's experience of pain or discomfort after the procedure. following each treatment administration and at the follow-up visits, subjects will be checked for immediate post-procedure adverse event assessment. in addition, at the last therapy visit, subjects will receive subject satisfaction and therapy comfort questionnaires to fill in. post-procedure evaluation (follow-up visits) will be conducted 2, 6 and 12 months after the final treatment. during those visits, magnetic resonance imaging, photographing and weight measure will be conducted. subject satisfaction questionnaire will be given at every follow-up visit.


Eligibility criteria:
inclusion criteria: * adult subjects of both genders with unwanted abdominal fat and expressing interest in treatment * age ≥ 22 years * voluntarily signed informed consent form * bmi ≤ 30 kg/m2 exclusion criteria: * cardiac pacemakers * electronic implants * pulmonary insufficiency * metal implants * drug pumps * haemorrhagic conditions * anticoagulation therapy * heart disorders * malignant tumor * fever * pregnancy * breastfeeding * following recent surgical procedures when muscle contraction may disrupt the healing process * application over menstruating uterus * application over areas of the skin which lack normal sensation * scars, open lesions and wounds at the treatment area * unrepaired abdominal hernia

Keywords: abdominal tissues
tibial nerve stimulation for faecal incontinence

Conditions: Fecal Incontinence

Summary: the purpose of this study is to determine whether tibial nerve stimulation is an effective treatment for faecal incontinence.

faecal incontinence is a common problem, affecting approximately 2% of the adult general population. initial management involves dietary advice, anti-diarrhoeal medication, and behavioural therapy. in those who have not benefited from these conservative techniques sacral nerve stimulation is an established and effective treatment for faecal incontinence. this treatment involves using electrical pulses to stimulate the s3 nerve root - a nerve at the bottom of the back. these are the nerves which supply the lower end of the bowel, and the anal sphincter. it is believed that it is stimulation of the sensory fibres heading back towards the spinal cord at this level which is important for the therapeutic effect. to stimulate the sacral nerves however requires two operations under general anaesthetic, and surgical implantation of an expensive nerve stimulator. the tibial nerve also contains fibres that arise from the s3 part of the spinal cord. electrical stimulation of the tibial nerve will therefore send sensory information back to the same region of the spinal cord as sacral nerve stimulation. the tibial nerve is much more easily accessible on the inside of the ankle, and this allows stimulation to be carried out as an outpatient and without the need for surgery. it can be performed either percutaneously (with a fine needle placed through the skin to sit next to the nerve), or transcutaneously. tibial nerve stimulation has been successfully used for patients with urinary incontinence. there are small studies looking at tibial nerve stimulation for faecal incontinence which both show a benefit, but these studies are not controlled. we aim to determine in a randomised controlled trial whether either percutaneous or transcutaneous tibial nerve stimulation is an effective treatment for faecal incontinence.

Eligibility criteria:
inclusion criteria: * over 18 * incontinence to solid or liquid faeces exclusion criteria: * previous congenital or acquired spinal injury, spinal tumour or spinal surgery * neurological diseases, such as diabetic neuropathy, multiple sclerosis and parkinson's disease * peripheral vascular disease * diabetes mellitus * congenital anorectal malformations * previous rectal surgery (rectopexy / resection) done \< 12 months ago (24 months for cancer) * present evidence of external full thickness rectal prolapse * chronic bowel diseases such as inflammatory bowel disease * chronic diarrhoea, uncontrolled by drugs or diet * anatomical limitations that would prevent successful placement of an electrode * previous use of transcutaneous electrical nerve stimulation stoma in situ
validation of a new score for ugi bleeding in the ed: the study of the tu-gib score

Conditions: Gastro Intestinal Bleed

Summary: we have developed a new reliable, easy and reproducible clinical and biological score to select patients presenting to the emergency department with upper gi bleeding and at high risk of developing complications in order to plan an adequate management. this score was compared to the glasgow-blatchford score and showed better results in predicting rebleeding, the need for hemostasis therapy and any complications at day 30 including mortality. in a second step and as an objective of this study, it is necessary to perform an external validation of this score in different emergency departments.

we have developed a new reliable, easy and reproducible clinical and biological score to select patients presenting to the emergency department with upper gi bleeding and at high risk of developing complications in order to plan an adequate management. this score was compared to the glasgow-blatchford score and showed better results in predicting rebleeding, the need for hemostasis therapy and any complications at day 30 including mortality. in a second step and as an objective of this study, it is necessary to perform an external validation of this score in different emergency departments. we will conduct a multicenter, descriptive and analytical study in different emergency departments inclusion criteria: patients consulting the emergency department for upper gi hemorrhage of non-traumatic origin. exclusion criteria: patients under 18 years of age, diagnosed with external hemorrhoids with parietal lesions. we exclude any patient who does not consent, is lost to follow-up or has incomplete information. anonymity and confidentiality of the data were respected. data collection was carried out using a data processing form designed for the purpose of this work, including descriptive analysis of the epidemiological and clinical characteristics of the patients, as well as the para-clinical data. patients were followed up by telephone call at d30 to record the date and cause of any complications noted, such as rebleeding, hospitalization, or death. the data will be entered and analyzed in spss 21.0

Eligibility criteria:
inclusion criteria: * patients consulting the emergency room for upper gi hemorrhage of non-traumatic origin. * age \>18 years exclusion criteria: * patient under the age of 18 * lower gastrointestinal hemorrhag * diagnosis of external hemorrhoids / perianal lesions * not consenting * the lost sight

Keywords: upper gastro intestinal bleeding; tu-gib score; ed
comparison of efficiency of interferential current application methods in chronic neck pain

Conditions: Chronic Neck Pain

Summary: the aim of this study is to evaluate the effects of interferential current therapy on pain, disability, and quality of life in patients with chronic neck pain and to compare the effects of applying interferential current therapy with vacuum electrodes versus carbon-silicon pad electrodes.

neck pain is quite common in the adult population and is a frequent reason for seeking medical attention. the prevalence of neck problems has increased with modern lifestyle changes. in individuals with neck pain, symptoms may resolve on their own within a few weeks, but approximately 30% of cases can become chronic. neck pain lasting 1-4 weeks is considered acute; 4-12 weeks is subacute; and neck pain persisting for 12 weeks or more is considered chronic. interferential current therapy is used in the treatment of chronic neck pain and is one of the physical therapy methods with analgesic effects. it is widely used around the world. interferential current therapy can be applied using two types of electrodes: vacuum electrodes and carbon-silicon pad electrodes.the aim of this study is to evaluate the effects of interferential current therapy on pain, disability, and quality of life in patients with chronic neck pain and to compare the effects of applying interferential current therapy with vacuum electrodes versus carbon-silicon pad electrodes

Eligibility criteria:
inclusion criteria: * patients with chronic neck pain lasting at least 3 months * ages between 20 and 50 years exclusion criteria: * patients with inflammatory or infectious diseases and those with radiculopathy or myelopathy symptoms * patients for whom electrotherapy is contraindicated (e.g., those with pregnancy, neurological conditions such as epilepsy, inner ear hearing aids, arrhythmias, pacemakers, active infections, skin lesions, etc.) * individuals with a history of malignancy, major surgery, or previous trauma * individuals who have received physical therapy within the last year * patients whose evaluation could not be completed for any reason * patients who do not wish to complete their evaluations for any reason
closure techniques and scar appearance

Conditions: Wound Closure Techniques

Summary: the goal of this study is to assess whether wound closure with skin adhesive or running stitches combined with skin adhesive will be superior to standard wound sutures. this is a split-wound study that will compare two methods of skin closure within one standard closure technique, thereby providing an internal control of running stitches within each wound. the investigators plan to measure outcomes by assessing for scar appearance, the incidence of wound opening, scar elasticity and subject satisfaction.


Eligibility criteria:
inclusion criteria: * age 18 and over * linear closures on the head and neck, at least 3cm in length * the subjects are in good health * the subject has the willingness and the ability to understand and provide informed consent for the use of their tissue and communicate with the investigator. exclusion criteria: * under 18 years of age * pregnancy or lactation * subjects who are unable to understand the protocol or to give informed consent * subjects with mental illness * defects on the scalp
lurasidone hcl a phase 3 study of patients with acute schizophrenia

Conditions: Schizophrenia

Summary: lurasidone hcl is a compound developed for the treatment of schizophrenia. this clinical study is designed to test the hypothesis that lurasidone is more efficacious than placebo. the study will also evaluate the safety and tolerability of lurasidone as compared to placebo.


Eligibility criteria:
inclusion criteria: * provide written informed consent and aged between 18 and 75 years of age. * meets dsm-iv criteria for a primary diagnosis of schizophrenia. * not pregnant, if of reproductive potential agrees to remain abstinent or use adequate and reliable contraception for duration of study. * able and agrees to remain off prior antipsychotic medication for the duration of study. * good physical health on the basis of medical history, physical examination, and laboratory screening. * willing and able to comply with the protocol, including the inpatient requirements and outpatient visits. exclusion criteria: * considered by the investigator to be at imminent risk of suicide or injury to self, others or property. * any chronic organic disease of the cns (other than schizophrenia). * used investigational compound within 30 days. * clinically significant or history of alcohol abuse/alcoholism or drug abuse/dependence within the last 6 months

Keywords: schizophrenia latuda lurasidone
glidescope videolaryngoscopy in patients with reduced mouth opening

Conditions: Intubation;Difficult; Videolaryngoscopy; Small Mouth

Summary: this study aims to evaluate the clinical performance, quality of larynx visualization and difficulty of videolaryngoscopic intubation in patients with a reduced mouth opening (1.0 to 3.0 cm) utilizing the latest generation of glidescopetm spectrum low profile laryngoscopy system.

reduced mouth opening in adults has been proven an important risk factor for difficult endotracheal intubation utilizing both direct and indirect laryngoscopy techniques, and a major reason for anesthesia-related adverse events. over the past two decades, videolaryngoscopy has evolved to be the primary indirect laryngoscopy technique in a difficult endotracheal intubation setting. the possibility for optimal visualization of the laryngeal structures renders this method particularly helpful in patients with limited mouth opening. especially videolaryngoscopy with acute-angle blades has been proposed to be favorable over conventional direct laryngoscopy in this setting. however, previous research has shown that a mouth opening of approximately 2.0 - 3.0 cm represents an independent risk factor and a possible critical lower limit for safe videolaryngoscopic intubation. the latest generation of glidescopetm spectrum blades may provide sufficient intubation conditions even in patients with a maximum mouth opening below 3.0 cm. our research group aims to evaluate the clinical performance, quality of larynx visualization and severity of videolaryngoscopic intubation the glidescopetm spectrum system in patients with a small mouth opening.

Eligibility criteria:
inclusion criteria: * patients scheduled for non-cardiac surgery * required general anesthesia and endotracheal intubation * mouth opening between 1.0 and 3.0 cm (any reason) recognized during preoperative assessment * written consent provided exclusion criteria: * pregnant or breastfeeding women * confirmed indication for awake fiberoptic intubation, especially due to enoral and pharyngeal tumors, abscesses or other obstructive lesions * endotracheal intubation planned without deep general anesthesia or without neuromuscular blockade (e.g. awake videolaryngoscopy) * qualification for rapid sequence anesthesia induction due to risk of pulmonary aspiration * loose teeth

Keywords: glidescope airway management videolaryngoscopic intubation
a study of ly3457263 alone and in combination with dulaglutide (ly2189265) in participants with type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: the main purpose of this study is to investigate the safety and tolerability of the study drug ly3457263 when administered alone or in combination with glucagon-like peptide 1 (glp-1) receptor agonist (ra) in participants with type 2 diabetes. blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. the study will last up to approximately 16 weeks excluding the screening period for each participant and include up to 17 visits.


Eligibility criteria:
inclusion criteria: * participants with type 2 diabetes (t2d) at least 6 months before screening * participants treated for t2d with diet and exercise, with or without metformin * have a glycated hemoglobin a1c (hba1c) value of ≥ 7.5% and ≤10.5% * have had a stable body weight for 3 months and body mass index (bmi) of 27.0 to 45.0 kilograms per meter squared (kg/m²) * male participants who agree to use effective methods of contraception and female participants not of childbearing potential exclusion criteria: * have a history of or current cardiovascular, respiratory, hepatic, renal, gi, endocrine (apart from t2d), hematological, or neurological disorders capable of altering the absorption, metabolism, or elimination of drugs * have type 1 diabetes mellitus or latent autoimmune diabetes in adults or maturity-onset diabetes of the young * have a history of proliferative diabetic retinopathy, diabetic maculopathy, or severe non-proliferative diabetic retinopathy * have known allergies to glp-1 receptor agonists
cdc-atn linkage evaluation

Conditions: HIV

Summary: the goal of atn 093 is to determine program-level factors associated with the effectiveness of smile in caring for youth linkage-to-care (ltc) program network at the 15 adolescent medicine trial units (amtu). this will be accomplished by evaluating and categorizing the various ltc programs at the amtus and then examining the association between the ltc program characteristics (providers, practices, and systems) and the proportion of human immunodeficiency virus (hiv)-infected youth, ages 12-24 years old, inclusive, linked to care and maintained in care. as such, this study focuses on ltc programs at the amtus as the unit of analysis and not the youth themselves.


Eligibility criteria:
inclusion criteria: * each enrolling site must have the capability to input field data that can be used to evaluate the effectiveness of the strategic multisite initiative for the identification, linkage, and engagement in care of youth with undiagnosed hiv infection (smile in caring for youth) project

Keywords: linkage to care hiv efficacy of linkage to care program
paxlovid in the treatment of covid-19 patients with uremia

Conditions: COVID-19; Uremia

Summary: this study is a single-center, open-label, randomized controlled clinical study to evaluate the effect of paxlovid on the virus-negative time and disease progression in uremic patients infected with sars-cov-2 (omicron variants). this study will enroll maintenance hemodialysis patients infected with sars-cov-2 (omicron variants). after signing the informed consent form, the qualified subjects will be randomly stratified 1:1 to standard-of-care (soc) or soc plus paxlovid for five days.


Eligibility criteria:
inclusion criteria: * sign informed consent. age ≥ 18 years old. covid-19 (nucleic acid test positive) was diagnosed before randomization. at least 1 symptom or sign of covid-19 at the time of being enrolled into the study(symptoms and signs related to covid-19 including cough, expectoration, dyspnea, fever, chills, fatigue, muscle soreness, diarrhea, headache, sore throat, stuffy nose, runny nose, etc.). exclusion criteria: * history of active liver disease, including chronic or active hepatitis b or c, primary biliary cirrhosis, child-pugh b or c, or acute liver failure. hiv infection and the viral load is greater than 400 copies/ml. suspected or confirmed active systemic infections that may have an impact on the study evaluation except for covid-19. acute heart failure, respiratory failure, severe chronic kidney disease, and cardiovascular disease caused by uremia-related complications. allergic to any ingredients of paxlovid.